US 11,718,611 B2
Benzenesulfonylbenazamide compound for inhibiting BCL-2 protein and composition and use thereof
Yihan Wang, Guangdong (CN); and Zhiqiang Liu, Guangdong (CN)
Assigned to Shenzhen TargetRx, Inc., Guangdong (CN)
Appl. No. 16/625,025
Filed by Shenzhen TargetRx, Inc., Guangdong (CN)
PCT Filed Jun. 25, 2018, PCT No. PCT/CN2018/092588
§ 371(c)(1), (2) Date Dec. 20, 2019,
PCT Pub. No. WO2019/001383, PCT Pub. Date Jan. 3, 2019.
Claims priority of application No. 201710493544.X (CN), filed on Jun. 26, 2017.
Prior Publication US 2020/0216442 A1, Jul. 9, 2020
Int. Cl. C07D 471/04 (2006.01); A61K 31/496 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01)
CPC C07D 471/04 (2013.01) 8 Claims
 
1. A compound represented by formula (I), or a pharmaceutically acceptable salt, prodrug, crystal form, stereoisomer, hydrate or solvate thereof:

OG Complex Work Unit Chemistry
wherein,
R1, R2, R3, R4, R5, R6, R7, and R8 are hydrogen;
R9 and R10 are deuterium;
R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29 R30, R31, R32, R33, R34, R35, R36, R37, R38, R39 and R40 are independently selected from hydrogen, deuterium, halogen and trifluoromethyl;
X1 and X2 are independently selected from the group consisting of hydrogen (H), deuterium (D), methyl, CH2D, CHD2, CD3, CH2CH3, CHDCH3, CHDCH2D, CHDCHD2, CHDCD3, CD2CH3, CD2CH2D, CD2CHD2 and CD2CD3;
the content of deuterium isotope in each deuterated position is at least greater than 50%.